Sarah Bitzer
Papers
1
Total Citations
66
H-Index
1
About
Dr. Sarah Bitzer is a leading figure in respiratory drug discovery, whose work has fundamentally advanced the development of physiologically relevant *in vitro* models. Her primary research focuses on miniaturizing and refining air-liquid interface (ALI) cultures of human airway epithelium, a critical tool for studying respiratory diseases and testing inhaled therapeutics. Her most impactful contribution, the "Development of a miniaturized 96-Transwell air–liquid interface human small airway epithelial model" (2020, 66 citations), directly tackles a major bottleneck in the field: the limited number of primary cells available from clinical samples. By successfully scaling down the traditional ALI model into a 96-well microplate format, Dr. Bitzer has enabled higher-throughput, more cost-effective screening of drug candidates and toxicological agents. This innovation not only conserves precious patient-derived cells but also accelerates the pace of preclinical research. Her work is a cornerstone for researchers seeking to bridge the gap between simple cell cultures and complex *in vivo* responses, making her a pivotal contributor to the future of respiratory medicine.
Research Focus
Key Achievements
Top Papers
- 1